BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Toripalimab: trial readouts and FDA decisions

4 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 4 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: RemeGen Co., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd., LaNova Medicines Limited, Suzhou Abogen Biosciences Co., Ltd.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12-30 est.P1/P2Suzhou Abogen Biosciences Co., Ltd.NCT06088004 Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid TumorsSolid Tumor, Adultrecruiting218
2026-12-31 est.P3RemeGen Co., Ltd.NCT05302284 A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial CarcinomaUrothelial Carcinoma; HER2-expressingrecruiting452
2026-12-31 est.P1/P2Mabwell (Shanghai) Bioscience Co., Ltd.NCT06079112 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial CancerAdvanced Urothelial Carcinomarecruiting100
2027-01-11 est.P1/P2LaNova Medicines LimitedNCT05615974 A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant TumorsMalignant Tumorsrecruiting139

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-31 est.P1/P2LaNova Medicines LimitedNCT05518045 A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid TumorsAdvanced Solid Tumoractive not recruiting392
2026-10-01 est.P2RemeGen Co., Ltd.NCT06642545 Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast CancerBreast Cancerrecruiting40
2026-06 est.P2Mabwell (Shanghai) Bioscience Co., Ltd.NCT06823427 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial CarcinomaUrothelial Carcinoma; Urothelial Carcinoma Bladder; Urothelial Carcinoma Recurrent; Urothelial Carcirecruiting60
2026-06 est.P2RemeGen Co., Ltd.NCT06178159 DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast CancerBreast Cancerrecruiting40

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.